Quercetin Phytosome® as a potential candidate for managing COVID-19

Pierro, Francesco Di; Khan, Amjad; Bertuccioli, Alexander; Maffioli, Pamela; Derosa, Giuseppe; Khan, Saeed; Khan, Bilal Ahmad; Nigar, Roohi; Ujjan, Ikram Din; Devrajani, Bikha Ram

doi:10.23736/s2724-5985.20.02771-3

Cited by 36 publications

(25 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although a number of synthetic compounds and natural compounds have been identified as SARS‐CoV‐2 3CL pro covalent inhibitors, most of them show poor bioavailability, poor metabolic stability, and poor aqueous solubility. In the future, the anti‐SARS‐CoV‐2 3CL pro potency and drug‐likeness properties should be improved simultaneously to overcome these limitations 306 …”

Section: Discussionmentioning

confidence: 99%

The SARS‐CoV‐2 main protease (M^pro): Structure, function, and emerging therapies for COVID‐19

Xiong

Zhu

et al. 2022

MedComm

130

View full text Add to dashboard Cite

The main proteases (Mpro), also termed 3‐chymotrypsin‐like proteases (3CLpro), are a class of highly conserved cysteine hydrolases in β‐coronaviruses. Increasing evidence has demonstrated that 3CLpros play an indispensable role in viral replication and have been recognized as key targets for preventing and treating coronavirus‐caused infectious diseases, including COVID‐19. This review is focused on the structural features and biological function of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) main protease Mpro (also known as 3CLpro), as well as recent advances in discovering and developing SARS‐CoV‐2 3CLpro inhibitors. To better understand the characteristics of SARS‐CoV‐2 3CLpro inhibitors, the inhibition activities, inhibitory mechanisms, and key structural features of various 3CLpro inhibitors (including marketed drugs, peptidomimetic, and non‐peptidomimetic synthetic compounds, as well as natural compounds and their derivatives) are summarized comprehensively. Meanwhile, the challenges in this field are highlighted, while future directions for designing and developing efficacious 3CLpro inhibitors as novel anti‐coronavirus therapies are also proposed. Collectively, all information and knowledge presented here are very helpful for understanding the structural features and inhibitory mechanisms of SARS‐CoV‐2 3CLpro inhibitors, which offers new insights or inspiration to medicinal chemists for designing and developing more efficacious 3CLpro inhibitors as novel anti‐coronavirus agents.

show abstract

Section: Discussionmentioning

confidence: 99%

The SARS‐CoV‐2 main protease (M^pro): Structure, function, and emerging therapies for COVID‐19

Xiong

Zhu

et al. 2022

MedComm

130

View full text Add to dashboard Cite

show abstract

“…To date, there is a considerable amount of data describing the safe profile and the potential antiviral, anti-inflammatory, and thrombin-inhibitory actions of quercetin [25,26].…”

Section: Discussionmentioning

confidence: 99%

Promising Effects of 3-Month Period of Quercetin Phytosome® Supplementation in the Prevention of Symptomatic COVID-19 Disease in Healthcare Workers: A Pilot Study

Rondanelli

Perna

Gasparri

et al. 2022

Life

View full text Add to dashboard Cite

Quercetin, for its crucial properties, fulfills the need for a multifactor action that is useful for the potential counterbalance of a COVID-19 infection. Given this background, the aim of the study was to evaluate the potential effect of 3 months’ supplementation with Quercetin Phytosome® (250 mg twice a day) as prevention against symptomatic COVID-19. In total, 120 subjects were enrolled (males, 63; females, 57; age 49 ± 12), with 60 in the supplementation group and 60 in the placebo group. No significant differences were detected between groups in terms of gender, smoking, and chronic disease. Subjects underwent rapid COVID-19 diagnostic tests every 3 weeks. During our study, 5 subjects had COVID-19, 1 out of 60 subjects in the quercetin group and 4 out of 60 in the control group. Complete clinical remission was recorded at 7 and 15 days in the quercetin and placebo groups, respectively. Analysis showed that, at 5 months, the COVID free survival function (risk of infection) was 99.8% in subjects under quercetin supplementation and 96.5% in control group. As shown by the value of EXP(B), those who had taken the supplement had a protection factor of 14% more to not contract the COVID-19 infection than that of those who had taken a placebo. Obtained results are encouraging, but further studies are required to add quercetin as regular prophylaxis.

show abstract

“…Quercetin, a well-known natural polyphenol with anti-inflammatory, antioxidant, and immunomodulatory properties, is involved in a variety of diseases, such as viral infections, respiratory diseases, allergies, asthma, and cancer ( Li Y. et al, 2016 ; Xu et al, 2019 ). Previous network pharmacology and molecular docking studies anticipated that quercetin could interfere with SARS-CoV-2 replication by interacting with 3-chymotrypsin-like protease (3CLpro), papain-like protease (PLpro), and S proteins ( Derosa et al, 2021 ; DI Pierro et al, 2021b ). An open-label, randomized controlled trial included 152 outpatients with confirmed SARS-CoV-2 infection but without severe COVID-19 symptoms found that formulated quercetin treatments reduced the frequency and length of hospitalization, the need of non-invasive oxygen therapy, and the number of deaths ( DI Pierro et al, 2021a ).…”

Section: Discussionmentioning

confidence: 99%

Bioinformatics and System Biology Approach to Reveal the Interaction Network and the Therapeutic Implications for Non-Small Cell Lung Cancer Patients With COVID-19

et al. 2022

View full text Add to dashboard Cite

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the leading cause of coronavirus disease-2019 (COVID-19), is an emerging global health crisis. Lung cancer patients are at a higher risk of COVID-19 infection. With the increasing number of non-small-cell lung cancer (NSCLC) patients with COVID-19, there is an urgent need of efficacious drugs for the treatment of COVID-19/NSCLC.Methods: Based on a comprehensive bioinformatic and systemic biological analysis, this study investigated COVID-19/NSCLC interactional hub genes, detected common pathways and molecular biomarkers, and predicted potential agents for COVID-19 and NSCLC.Results: A total of 122 COVID-19/NSCLC interactional genes and 21 interactional hub genes were identified. The enrichment analysis indicated that COVID-19 and NSCLC shared common signaling pathways, including cell cycle, viral carcinogenesis, and p53 signaling pathway. In total, 10 important transcription factors (TFs) and 44 microRNAs (miRNAs) participated in regulations of 21 interactional hub genes. In addition, 23 potential candidates were predicted for the treatment of COVID-19 and NSCLC.Conclusion: This study increased our understanding of pathophysiology and screened potential drugs for COVID-19 and NSCLC.

show abstract

Quercetin Phytosome® as a potential candidate for managing COVID-19

Cited by 36 publications

References 34 publications

The SARS‐CoV‐2 main protease (M^pro): Structure, function, and emerging therapies for COVID‐19

The SARS‐CoV‐2 main protease (M^pro): Structure, function, and emerging therapies for COVID‐19

Promising Effects of 3-Month Period of Quercetin Phytosome® Supplementation in the Prevention of Symptomatic COVID-19 Disease in Healthcare Workers: A Pilot Study

Bioinformatics and System Biology Approach to Reveal the Interaction Network and the Therapeutic Implications for Non-Small Cell Lung Cancer Patients With COVID-19

Contact Info

Product

Resources

About

Quercetin Phytosome® as a potential candidate for managing COVID-19

Cited by 36 publications

References 34 publications

The SARS‐CoV‐2 main protease (Mpro): Structure, function, and emerging therapies for COVID‐19

The SARS‐CoV‐2 main protease (Mpro): Structure, function, and emerging therapies for COVID‐19

Promising Effects of 3-Month Period of Quercetin Phytosome® Supplementation in the Prevention of Symptomatic COVID-19 Disease in Healthcare Workers: A Pilot Study

Bioinformatics and System Biology Approach to Reveal the Interaction Network and the Therapeutic Implications for Non-Small Cell Lung Cancer Patients With COVID-19

Contact Info

Product

Resources

About

The SARS‐CoV‐2 main protease (M^pro): Structure, function, and emerging therapies for COVID‐19

The SARS‐CoV‐2 main protease (M^pro): Structure, function, and emerging therapies for COVID‐19